

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of
Stephen John Minshull et al.

Examiner: **Steven O Douglas**

Art Unit: **3771**

Application No.: **10/665,873**

Confirmation No. **6763**

Filed: **September 18, 2003**

Title: **INHALER**

CERTIFICATE OF EFS-WEB TRANSMISSION

I hereby certify that the correspondence below is being transmitted via the USPTO's electronic filing system in accordance with 1.6(a)(4), on the date indicated below.

Date of Deposit March 9, 2011

Printed Name of Person

Signing Certificate Brian Pritchett

Signature /Brian Pritchett/

REQUEST FOR CERTIFICATE OF CORRECTION
UNDER 35 U.S.C. 254/255 and 37 C.F.R. 1.322/323

Mail Stop
Commissioner for Patents
P. O. Box 1450
Alexandria, VA 22313-1450

The following is a request for a certificate of correction in Serial Number 10/665,873, now patent Number 7,322,352.

A certificate of correction under 35 U.S.C. 254 is respectfully requested in the above-identified patent.

- ☐ All errors were the fault of the USPTO, no fee required. In the event that a further fee is required, please charge the amount to Deposit Account No. **18-1982**.
- ☐ All errors were the fault of the applicant and, accordingly, please charge **\$100.00** to our Deposit Account No. **18-1982**. In the event that a further fee is required, please charge the amount to the same Deposit Account.
- ☒ The errors were the fault of both the applicant and the USPTO and, accordingly, please charge **\$100.00** to our Deposit Account No. **18-1982**. In the event that a further fee is required, please charge the amount to the same Deposit Account.

The exact location where the error appears in the patent and patent application is noted below.

The requested correction is attached on Form PTO 1050.

EXACT LOCATION WHERE ERRORS APPEAR

1. In column 8, line 12 (Page 9, Specification, (09/18/2003), line 31):
“teraphthalate,” should read as - - terephthalate, - -.
2. In column 8, line 28 (Page 10, Specification, (09/18/2003), line 4):
“mnethapyfilene;” should read as - - methapyrilene; - -.
3. In column 8, line 30 (Page 10, Specification, (09/18/2003), line 6):
“forinoterol,” should read as - - formoterol, - -.
4. In column 8, line 42 (Page 10, Specification, (09/18/2003), line 13):
“oxftropium;” should read as - - oxitropium; - -.
5. In column 8, line 43 (Page 10, Specification, (09/18/2003), line 13):
“hydrocordisone” should read as - - hydrocortisone - -.
6. In column 8, line 52 (Page 10, Specification, (09/18/2003), line 19):
“leukotrine” should read as - - leukotriene - -.
7. In column 15, line 6 (Page 14, Claims, (08/15/2007), claim 48, line 1): in
Claim 32, “f or” should read as - - for - -.
8. In column 20, line 4 (Page 27, Claims, (08/15/2007), claim 109, line 2): in
Claim 75, “claim 73,” should read as - - claim 74, - -.

Respectfully submitted,

/Timothy M. Salmon/

Timothy M. Salmon, Reg. No. 54,420
Attorney/Agent for Applicant

Sanofi-aventis U.S. Inc.
U.S. Patent Operations
Mail Code: BWD-303A
1041 Route 202-206
Bridgewater, New Jersey 08807
Telephone (908) 231-2387
Telefax (908) 231-2626
Sanofi-aventis U.S. Docket No. USAV2001/0079 US NP
Date: March 9, 2011